Moreover, similarly to familial AD and ALS, NfL levels present a higher increase rate near clinical onset [20], representing a useful tool for detecting converters who could benefit from a disease-modifying treatment. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.